Urogen Pharma (NASDAQ:URGN) has been assigned a $51.00 price objective by equities researchers at Oppenheimer Holdings, Inc. in a note issued to investors on Tuesday. The brokerage presently has an “outperform” rating on the stock. Oppenheimer Holdings, Inc.’s target price suggests a potential upside of 20.91% from the company’s current price.

A number of other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Urogen Pharma from a “hold” rating to a “sell” rating in a report on Thursday, September 14th. Jefferies Group LLC increased their price target on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $33.25.

Shares of Urogen Pharma (NASDAQ URGN) traded down $1.08 during trading hours on Tuesday, hitting $42.18. 127,100 shares of the stock were exchanged, compared to its average volume of 59,653. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $44.63.

ILLEGAL ACTIVITY WARNING: “Urogen Pharma (URGN) PT Set at $51.00 by Oppenheimer Holdings, Inc.” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/urogen-pharma-urgn-given-a-51-00-price-target-at-oppenheimer-holdings-inc/1704229.html.

Institutional investors have recently made changes to their positions in the company. State of Tennessee Treasury Department purchased a new stake in shares of Urogen Pharma in the 3rd quarter valued at $158,000. JPMorgan Chase & Co. purchased a new stake in shares of Urogen Pharma in the 3rd quarter valued at $168,000. Alps Advisors Inc. purchased a new stake in shares of Urogen Pharma in the 2nd quarter valued at $195,000. Shikiar Asset Management Inc. purchased a new stake in shares of Urogen Pharma in the 3rd quarter valued at $665,000. Finally, LLBH Private Wealth Management LLC purchased a new stake in shares of Urogen Pharma in the 2nd quarter valued at $695,000. 40.55% of the stock is owned by institutional investors.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.